| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tunica Intima | 22 | 2014 | 76 | 1.320 |
Why?
|
| Hypertension | 21 | 2018 | 980 | 1.150 |
Why?
|
| Antihypertensive Agents | 13 | 2018 | 363 | 1.000 |
Why?
|
| Carotid Artery, Common | 10 | 2014 | 48 | 0.910 |
Why?
|
| Carotid Artery Diseases | 14 | 2015 | 126 | 0.870 |
Why?
|
| Cardiovascular Diseases | 15 | 2018 | 1159 | 0.820 |
Why?
|
| Diabetes Mellitus, Type 2 | 12 | 2017 | 1437 | 0.690 |
Why?
|
| Atherosclerosis | 15 | 2017 | 821 | 0.680 |
Why?
|
| Fluorobenzenes | 11 | 2012 | 32 | 0.680 |
Why?
|
| Carotid Arteries | 17 | 2014 | 109 | 0.670 |
Why?
|
| Sulfonamides | 11 | 2012 | 86 | 0.660 |
Why?
|
| Pyrimidines | 11 | 2012 | 77 | 0.650 |
Why?
|
| Blood Pressure | 17 | 2018 | 864 | 0.640 |
Why?
|
| Middle Aged | 71 | 2018 | 11837 | 0.630 |
Why?
|
| Female | 76 | 2018 | 19935 | 0.520 |
Why?
|
| Tunica Media | 10 | 2014 | 39 | 0.510 |
Why?
|
| Air Pollutants | 4 | 2019 | 26 | 0.500 |
Why?
|
| Male | 71 | 2018 | 19429 | 0.500 |
Why?
|
| Particulate Matter | 4 | 2019 | 32 | 0.500 |
Why?
|
| Humans | 89 | 2018 | 32262 | 0.460 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 9 | 2013 | 167 | 0.440 |
Why?
|
| Aged | 39 | 2018 | 10249 | 0.430 |
Why?
|
| Risk Factors | 31 | 2018 | 3933 | 0.400 |
Why?
|
| Carbon | 1 | 2013 | 13 | 0.400 |
Why?
|
| Geography | 1 | 2013 | 30 | 0.400 |
Why?
|
| Blood Flow Velocity | 1 | 2012 | 77 | 0.370 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 34 | 0.370 |
Why?
|
| Myocardial Infarction | 9 | 2016 | 466 | 0.360 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 92 | 0.360 |
Why?
|
| Accidental Falls | 4 | 2018 | 104 | 0.360 |
Why?
|
| Government | 1 | 2010 | 4 | 0.330 |
Why?
|
| Industry | 1 | 2010 | 15 | 0.330 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 59 | 0.320 |
Why?
|
| Heptanoic Acids | 6 | 2013 | 33 | 0.320 |
Why?
|
| Pyrroles | 6 | 2013 | 59 | 0.320 |
Why?
|
| Food Additives | 1 | 2010 | 2 | 0.320 |
Why?
|
| Food Labeling | 1 | 2010 | 2 | 0.320 |
Why?
|
| Food Handling | 1 | 2010 | 7 | 0.320 |
Why?
|
| Ultrasonography | 19 | 2011 | 393 | 0.310 |
Why?
|
| Heart Rate | 8 | 2010 | 364 | 0.310 |
Why?
|
| Food | 1 | 2010 | 42 | 0.310 |
Why?
|
| Cohort Studies | 17 | 2018 | 1839 | 0.300 |
Why?
|
| Perception | 1 | 2010 | 99 | 0.300 |
Why?
|
| Sex Factors | 9 | 2018 | 656 | 0.280 |
Why?
|
| Quinolines | 5 | 2010 | 29 | 0.280 |
Why?
|
| Adult | 25 | 2018 | 9252 | 0.280 |
Why?
|
| Aging | 2 | 2012 | 942 | 0.280 |
Why?
|
| Double-Blind Method | 16 | 2016 | 566 | 0.270 |
Why?
|
| Radiation Protection | 2 | 2018 | 11 | 0.260 |
Why?
|
| Risk Assessment | 8 | 2018 | 1423 | 0.260 |
Why?
|
| Stroke | 6 | 2015 | 691 | 0.250 |
Why?
|
| Glomerular Filtration Rate | 3 | 2017 | 302 | 0.250 |
Why?
|
| Hypotension, Orthostatic | 2 | 2016 | 12 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 10 | 2016 | 544 | 0.240 |
Why?
|
| Arteriosclerosis | 7 | 2005 | 147 | 0.240 |
Why?
|
| Cross-Sectional Studies | 13 | 2018 | 1478 | 0.230 |
Why?
|
| Brain | 1 | 2012 | 966 | 0.230 |
Why?
|
| Coronary Artery Disease | 6 | 2007 | 427 | 0.220 |
Why?
|
| United States | 18 | 2018 | 4068 | 0.220 |
Why?
|
| Adolescent | 10 | 2018 | 3509 | 0.210 |
Why?
|
| Posture | 3 | 2016 | 62 | 0.210 |
Why?
|
| Proportional Hazards Models | 10 | 2018 | 772 | 0.200 |
Why?
|
| Anticholesteremic Agents | 6 | 2012 | 47 | 0.200 |
Why?
|
| Diabetes Mellitus | 6 | 2015 | 390 | 0.200 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2017 | 293 | 0.200 |
Why?
|
| Reproducibility of Results | 8 | 2013 | 756 | 0.200 |
Why?
|
| Coronary Disease | 6 | 2004 | 226 | 0.190 |
Why?
|
| Fractures, Bone | 2 | 2015 | 142 | 0.190 |
Why?
|
| Dyslipidemias | 4 | 2015 | 60 | 0.190 |
Why?
|
| Disease Progression | 11 | 2013 | 591 | 0.190 |
Why?
|
| Echocardiography | 3 | 2013 | 190 | 0.190 |
Why?
|
| Blood Pressure Determination | 3 | 2018 | 106 | 0.190 |
Why?
|
| Body Mass Index | 4 | 2009 | 863 | 0.190 |
Why?
|
| Heart Failure | 3 | 2017 | 728 | 0.170 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 556 | 0.170 |
Why?
|
| Follow-Up Studies | 12 | 2016 | 2238 | 0.170 |
Why?
|
| Prevalence | 9 | 2017 | 955 | 0.160 |
Why?
|
| Oxidative Stress | 3 | 2019 | 255 | 0.160 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 133 | 0.160 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2013 | 149 | 0.160 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2010 | 20 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 3893 | 0.150 |
Why?
|
| Incidence | 9 | 2015 | 1241 | 0.150 |
Why?
|
| Technology, Radiologic | 1 | 2018 | 2 | 0.150 |
Why?
|
| Prospective Studies | 13 | 2015 | 2315 | 0.150 |
Why?
|
| Respiratory Tract Diseases | 2 | 2016 | 34 | 0.150 |
Why?
|
| Contracts | 1 | 2018 | 7 | 0.150 |
Why?
|
| Financing, Government | 1 | 2018 | 11 | 0.140 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2018 | 20 | 0.140 |
Why?
|
| Time Factors | 10 | 2018 | 2203 | 0.140 |
Why?
|
| Age Factors | 7 | 2018 | 1178 | 0.140 |
Why?
|
| Environmental Exposure | 2 | 2016 | 60 | 0.140 |
Why?
|
| Neoplasms | 2 | 2016 | 757 | 0.140 |
Why?
|
| Obesity, Abdominal | 1 | 2018 | 24 | 0.140 |
Why?
|
| Cholesterol Ester Transfer Proteins | 2 | 2008 | 13 | 0.140 |
Why?
|
| Syncope | 1 | 2018 | 25 | 0.140 |
Why?
|
| Hypotension | 1 | 2018 | 43 | 0.130 |
Why?
|
| Research Design | 4 | 2012 | 316 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2016 | 3408 | 0.130 |
Why?
|
| Smoking | 7 | 2017 | 505 | 0.130 |
Why?
|
| Continental Population Groups | 3 | 2015 | 228 | 0.130 |
Why?
|
| Linear Models | 5 | 2017 | 426 | 0.130 |
Why?
|
| Carotid Stenosis | 3 | 2007 | 59 | 0.120 |
Why?
|
| Biomedical Research | 2 | 2016 | 178 | 0.120 |
Why?
|
| Gasoline | 1 | 2016 | 2 | 0.120 |
Why?
|
| Vehicle Emissions | 1 | 2016 | 4 | 0.120 |
Why?
|
| Occupational Exposure | 1 | 2018 | 159 | 0.120 |
Why?
|
| Comorbidity | 5 | 2018 | 563 | 0.120 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2016 | 19 | 0.120 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 2016 | 9 | 0.120 |
Why?
|
| Young Adult | 5 | 2016 | 2643 | 0.120 |
Why?
|
| Albuminuria | 1 | 2017 | 172 | 0.120 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 255 | 0.120 |
Why?
|
| North Carolina | 3 | 2012 | 1300 | 0.120 |
Why?
|
| Prescription Drugs | 1 | 2016 | 19 | 0.120 |
Why?
|
| Clinical Trials as Topic | 3 | 2012 | 312 | 0.110 |
Why?
|
| Autonomic Nervous System | 4 | 2003 | 50 | 0.110 |
Why?
|
| Sexual Behavior | 1 | 2016 | 130 | 0.110 |
Why?
|
| Diet Therapy | 1 | 2015 | 17 | 0.110 |
Why?
|
| Lung | 1 | 2016 | 263 | 0.110 |
Why?
|
| European Continental Ancestry Group | 4 | 2014 | 1076 | 0.110 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2013 | 103 | 0.110 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2015 | 122 | 0.110 |
Why?
|
| Tissue Expansion | 1 | 2014 | 6 | 0.110 |
Why?
|
| Osteoporosis | 2 | 2006 | 51 | 0.110 |
Why?
|
| Tissue Expansion Devices | 1 | 2014 | 12 | 0.110 |
Why?
|
| Breast Implantation | 1 | 2014 | 9 | 0.100 |
Why?
|
| Sample Size | 2 | 2012 | 38 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2014 | 484 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2013 | 227 | 0.100 |
Why?
|
| Longitudinal Studies | 5 | 2012 | 759 | 0.100 |
Why?
|
| Biomass | 1 | 2013 | 4 | 0.100 |
Why?
|
| Age Distribution | 5 | 2016 | 194 | 0.100 |
Why?
|
| Atmosphere | 1 | 2013 | 2 | 0.100 |
Why?
|
| Calcinosis | 2 | 2004 | 142 | 0.100 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 76 | 0.100 |
Why?
|
| Tick-Borne Diseases | 1 | 2013 | 1 | 0.100 |
Why?
|
| Ethnic Groups | 1 | 2015 | 450 | 0.100 |
Why?
|
| Exercise Therapy | 1 | 2015 | 249 | 0.090 |
Why?
|
| Motor Activity | 1 | 2015 | 332 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 444 | 0.090 |
Why?
|
| Norpregnenes | 3 | 2010 | 28 | 0.090 |
Why?
|
| Reference Values | 1 | 2012 | 238 | 0.090 |
Why?
|
| Biometry | 1 | 2012 | 14 | 0.090 |
Why?
|
| Cholesterol, LDL | 5 | 2015 | 170 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2003 | 216 | 0.090 |
Why?
|
| Atrial Fibrillation | 1 | 2016 | 410 | 0.090 |
Why?
|
| Educational Status | 2 | 2010 | 167 | 0.090 |
Why?
|
| Placebos | 4 | 2012 | 68 | 0.090 |
Why?
|
| Cholesterol | 2 | 2017 | 262 | 0.090 |
Why?
|
| Predictive Value of Tests | 6 | 2012 | 880 | 0.090 |
Why?
|
| Personnel, Hospital | 1 | 2010 | 12 | 0.080 |
Why?
|
| Obesity | 2 | 2015 | 1111 | 0.080 |
Why?
|
| Postmenopause | 2 | 2010 | 424 | 0.080 |
Why?
|
| Meditation | 1 | 2010 | 28 | 0.080 |
Why?
|
| Carotid Artery, Internal | 1 | 2010 | 33 | 0.080 |
Why?
|
| Cardiology | 1 | 2011 | 104 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2010 | 83 | 0.080 |
Why?
|
| Food Analysis | 1 | 2010 | 7 | 0.080 |
Why?
|
| Nutritive Value | 1 | 2010 | 10 | 0.080 |
Why?
|
| Autonomic Nervous System Diseases | 1 | 2010 | 12 | 0.080 |
Why?
|
| Diabetic Neuropathies | 1 | 2010 | 28 | 0.080 |
Why?
|
| Vegetables | 1 | 2010 | 39 | 0.080 |
Why?
|
| Fruit | 1 | 2010 | 51 | 0.080 |
Why?
|
| Hormone Replacement Therapy | 1 | 2010 | 94 | 0.080 |
Why?
|
| Medroxyprogesterone Acetate | 2 | 2010 | 112 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 854 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 98 | 0.070 |
Why?
|
| Diabetic Angiopathies | 2 | 2007 | 150 | 0.070 |
Why?
|
| Systole | 3 | 2016 | 94 | 0.070 |
Why?
|
| Survival Analysis | 4 | 2018 | 476 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2010 | 227 | 0.070 |
Why?
|
| Body Composition | 1 | 2010 | 327 | 0.070 |
Why?
|
| Creatinine | 3 | 2017 | 191 | 0.070 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2006 | 157 | 0.070 |
Why?
|
| Canada | 2 | 2019 | 63 | 0.070 |
Why?
|
| Environmental Monitoring | 2 | 2019 | 14 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2012 | 171 | 0.060 |
Why?
|
| Heart Arrest | 1 | 2007 | 42 | 0.060 |
Why?
|
| Uric Acid | 1 | 2006 | 26 | 0.060 |
Why?
|
| Mississippi | 2 | 2004 | 38 | 0.060 |
Why?
|
| African Americans | 3 | 2014 | 1335 | 0.060 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2006 | 12 | 0.060 |
Why?
|
| Sex Distribution | 3 | 2016 | 174 | 0.060 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2006 | 26 | 0.060 |
Why?
|
| Meta-Analysis as Topic | 2 | 2017 | 47 | 0.060 |
Why?
|
| Algorithms | 4 | 2012 | 536 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2005 | 28 | 0.060 |
Why?
|
| Confidence Intervals | 2 | 2018 | 141 | 0.060 |
Why?
|
| African Continental Ancestry Group | 2 | 2004 | 338 | 0.050 |
Why?
|
| Risk | 3 | 2012 | 305 | 0.050 |
Why?
|
| Heart Conduction System | 2 | 2002 | 76 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2005 | 50 | 0.050 |
Why?
|
| Cholesterol, HDL | 3 | 2015 | 181 | 0.050 |
Why?
|
| Body Height | 2 | 2016 | 34 | 0.050 |
Why?
|
| Prognosis | 3 | 2016 | 1529 | 0.050 |
Why?
|
| Periodontitis | 1 | 2004 | 10 | 0.050 |
Why?
|
| Overweight | 2 | 2017 | 252 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2005 | 174 | 0.050 |
Why?
|
| Chromosomes, Human | 1 | 2004 | 9 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2016 | 455 | 0.050 |
Why?
|
| Calcium | 1 | 2005 | 339 | 0.050 |
Why?
|
| Multivariate Analysis | 4 | 2007 | 650 | 0.050 |
Why?
|
| Long QT Syndrome | 1 | 2003 | 44 | 0.050 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 12 | 0.050 |
Why?
|
| Insulin | 1 | 2005 | 359 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2003 | 43 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2003 | 59 | 0.050 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 45 | 0.050 |
Why?
|
| Amlodipine | 1 | 2002 | 15 | 0.050 |
Why?
|
| Logistic Models | 4 | 2007 | 743 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 72 | 0.050 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 53 | 0.050 |
Why?
|
| Vasectomy | 1 | 2002 | 1 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2002 | 87 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2004 | 821 | 0.040 |
Why?
|
| Quality of Life | 2 | 2016 | 968 | 0.040 |
Why?
|
| Wounds and Injuries | 1 | 2002 | 241 | 0.040 |
Why?
|
| Europe | 2 | 2012 | 82 | 0.040 |
Why?
|
| Cities | 1 | 2019 | 7 | 0.040 |
Why?
|
| China | 1 | 2018 | 56 | 0.030 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2018 | 33 | 0.030 |
Why?
|
| Sweden | 1 | 2017 | 16 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2010 | 31 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2017 | 120 | 0.030 |
Why?
|
| Child | 2 | 2016 | 2430 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2017 | 101 | 0.030 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2016 | 12 | 0.030 |
Why?
|
| Government Agencies | 1 | 2016 | 6 | 0.030 |
Why?
|
| Heme Oxygenase-1 | 1 | 2016 | 35 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 292 | 0.030 |
Why?
|
| Colorado | 1 | 2016 | 43 | 0.030 |
Why?
|
| Physical Fitness | 1 | 2017 | 120 | 0.030 |
Why?
|
| Fires | 1 | 2016 | 9 | 0.030 |
Why?
|
| Ontario | 1 | 2015 | 5 | 0.030 |
Why?
|
| Estrogens | 2 | 2010 | 194 | 0.030 |
Why?
|
| Environmental Health | 1 | 2015 | 7 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2016 | 196 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 95 | 0.030 |
Why?
|
| Particle Size | 1 | 2015 | 48 | 0.030 |
Why?
|
| Megakaryocyte Progenitor Cells | 1 | 2015 | 1 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2017 | 246 | 0.030 |
Why?
|
| Toll-Like Receptor 5 | 1 | 2015 | 11 | 0.030 |
Why?
|
| Genistein | 1 | 2015 | 17 | 0.030 |
Why?
|
| Thrombin | 1 | 2015 | 25 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2016 | 274 | 0.030 |
Why?
|
| Public Health | 1 | 2016 | 91 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2017 | 854 | 0.030 |
Why?
|
| Netherlands | 1 | 2015 | 25 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2015 | 92 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2007 | 276 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2016 | 243 | 0.030 |
Why?
|
| Probability | 2 | 2007 | 155 | 0.030 |
Why?
|
| ROC Curve | 2 | 2007 | 169 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2014 | 44 | 0.030 |
Why?
|
| Diet, Reducing | 1 | 2015 | 85 | 0.030 |
Why?
|
| Breast Implants | 1 | 2014 | 3 | 0.030 |
Why?
|
| Electrocardiography | 3 | 2004 | 624 | 0.030 |
Why?
|
| Lipids | 2 | 2007 | 253 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2014 | 25 | 0.030 |
Why?
|
| Self Care | 1 | 2015 | 97 | 0.030 |
Why?
|
| Brachial Artery | 2 | 2005 | 72 | 0.030 |
Why?
|
| Patient Selection | 2 | 2007 | 272 | 0.030 |
Why?
|
| Survival Rate | 1 | 2016 | 892 | 0.030 |
Why?
|
| Simvastatin | 1 | 2014 | 26 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 2014 | 35 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 666 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2004 | 99 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2016 | 3609 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2014 | 117 | 0.020 |
Why?
|
| Tick Infestations | 1 | 2013 | 1 | 0.020 |
Why?
|
| Clothing | 1 | 2013 | 5 | 0.020 |
Why?
|
| Insecticides | 1 | 2013 | 15 | 0.020 |
Why?
|
| Puberty | 1 | 2013 | 8 | 0.020 |
Why?
|
| Disease Management | 1 | 2014 | 129 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 245 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 8196 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1010 | 0.020 |
Why?
|
| Coronary Angiography | 2 | 2004 | 159 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2004 | 273 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2015 | 415 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2012 | 11 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 91 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2016 | 1233 | 0.020 |
Why?
|
| Waist Circumference | 1 | 2012 | 91 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2012 | 52 | 0.020 |
Why?
|
| Placebo Effect | 1 | 2011 | 18 | 0.020 |
Why?
|
| Rural Population | 1 | 2013 | 216 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 187 | 0.020 |
Why?
|
| Congresses as Topic | 1 | 2010 | 42 | 0.020 |
Why?
|
| Inservice Training | 1 | 2010 | 12 | 0.020 |
Why?
|
| Mice | 1 | 2016 | 2571 | 0.020 |
Why?
|
| Nonlinear Dynamics | 1 | 2010 | 77 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2010 | 16 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 316 | 0.020 |
Why?
|
| Hemorrhage | 1 | 2010 | 95 | 0.020 |
Why?
|
| Hyperglycemia | 1 | 2010 | 85 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2004 | 904 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2010 | 161 | 0.020 |
Why?
|
| Azathioprine | 1 | 2009 | 27 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 69 | 0.020 |
Why?
|
| Radiography | 1 | 2010 | 358 | 0.020 |
Why?
|
| Mineralocorticoids | 1 | 2008 | 6 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2009 | 95 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 177 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 186 | 0.020 |
Why?
|
| Hispanic Americans | 1 | 2012 | 772 | 0.020 |
Why?
|
| Hyperlipidemia, Familial Combined | 1 | 2007 | 4 | 0.020 |
Why?
|
| Heterozygote | 1 | 2007 | 60 | 0.020 |
Why?
|
| Organ Size | 1 | 2007 | 221 | 0.020 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2006 | 19 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2007 | 716 | 0.010 |
Why?
|
| Vascular Resistance | 1 | 2005 | 32 | 0.010 |
Why?
|
| Forced Expiratory Volume | 1 | 2005 | 81 | 0.010 |
Why?
|
| Models, Biological | 1 | 2007 | 408 | 0.010 |
Why?
|
| Laboratories | 1 | 2004 | 18 | 0.010 |
Why?
|
| Research | 1 | 2004 | 81 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 110 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2004 | 31 | 0.010 |
Why?
|
| Diastole | 1 | 2004 | 98 | 0.010 |
Why?
|
| Social Class | 1 | 2004 | 90 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2004 | 124 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2004 | 108 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2003 | 126 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2003 | 55 | 0.010 |
Why?
|
| Progestins | 1 | 2003 | 27 | 0.010 |
Why?
|
| Random Allocation | 1 | 2003 | 247 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 102 | 0.010 |
Why?
|
| Disease | 1 | 2002 | 5 | 0.010 |
Why?
|
| Bone Density | 1 | 2003 | 169 | 0.010 |
Why?
|
| Coronary Restenosis | 1 | 2002 | 15 | 0.010 |
Why?
|
| Abbreviated Injury Scale | 1 | 2002 | 57 | 0.010 |
Why?
|
| Parasympathetic Nervous System | 1 | 2002 | 4 | 0.010 |
Why?
|
| Supine Position | 1 | 2002 | 11 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2002 | 110 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 60 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 2002 | 34 | 0.010 |
Why?
|
| Apolipoprotein E4 | 1 | 2002 | 56 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2002 | 211 | 0.010 |
Why?
|
| Cause of Death | 1 | 2002 | 236 | 0.010 |
Why?
|
| Glucose | 1 | 2002 | 160 | 0.010 |
Why?
|
| Alleles | 1 | 2002 | 250 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 287 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 413 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2003 | 458 | 0.010 |
Why?
|
| Inflammation | 1 | 2002 | 507 | 0.010 |
Why?
|